EPM
GNMK

Equitec Proprietary Markets’s GenMark Diagnostics, Inc GNMK Stock Holding History

Equitec Proprietary Markets’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$366K Buy
+15,300
New +$71.7K 0.12% 63

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Equitec Proprietary Markets's GNMK Position: Q1 2020 in Review

Equitec Proprietary Markets opened a new position in GenMark Diagnostics, Inc (GNMK) in Q1 2020: 15,300 shares worth $366K. The stake represents 0.12% of the portfolio and ranks #63 among its holdings.

110 funds tracked by Wall St. Rank hold GNMK as of Q1 2020.

  • Equitec Proprietary Markets held 15,300 shares of GenMark Diagnostics, Inc worth $366K as of Q1 2020.
  • GenMark Diagnostics, Inc was a new Equitec Proprietary Markets position in Q1 2020.
  • GenMark Diagnostics, Inc made up 0.12% of Equitec Proprietary Markets's portfolio in Q1 2020, its #63 holding.
  • 110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2020.

Based on Equitec Proprietary Markets's 13F filing for Q1 2020, filed 19 Apr 2021.